Adlai Nortye (NASDAQ:ANL) Rating Reiterated by Cantor Fitzgerald

Cantor Fitzgerald reissued their overweight rating on shares of Adlai Nortye (NASDAQ:ANLFree Report) in a report published on Thursday, Benzinga reports.

Adlai Nortye Stock Up 1.1 %

Shares of ANL stock opened at $3.65 on Thursday. Adlai Nortye has a 52-week low of $3.21 and a 52-week high of $19.30. The firm’s 50 day moving average price is $9.81 and its two-hundred day moving average price is $9.22.

Institutional Investors Weigh In On Adlai Nortye

An institutional investor recently raised its position in Adlai Nortye stock. Cantor Fitzgerald L. P. lifted its position in shares of Adlai Nortye Ltd. (NASDAQ:ANLFree Report) by 128.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 40,310 shares of the company’s stock after purchasing an additional 22,644 shares during the period. Cantor Fitzgerald L. P. owned 0.11% of Adlai Nortye worth $362,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 35.21% of the company’s stock.

Adlai Nortye Company Profile

(Get Free Report)

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.

Recommended Stories

Receive News & Ratings for Adlai Nortye Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adlai Nortye and related companies with MarketBeat.com's FREE daily email newsletter.